StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-07 | $9.85 | $9.66 | -1.93% | 0.0M |
| 05-08 | $9.75 | $9.95 | +2.05% | 0.0M |
| 05-11 | $10.03 | $10.05 | +0.20% | 0.1M |
| 05-12 | $10.50 | $10.50 | +0.00% | 0.0M |
| 05-15 | $10.75 | $10.75 | -0.00% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2011 2011-12-31 | Q3 2011 2011-09-30 | Q2 2011 2011-06-30 | Annual 2010 2010-12-31 |
|---|---|---|---|---|
Revenue | $1.45M | $1.08M | $735.61K | $1.58M |
Operating Income | $-5.79M | $-4.78M | $-3.52M | $-5.66M |
Net Income | $-7.19M | $-5.69M | $-1.51M | $4.97M |
EPS (Diluted) | Not available | Not available | Not available | Not available |
Total Assets | $85.72M | $88.25M | $96.24M | $91.20M |
Total Liabilities | $49.51M | $50.63M | $50.66M | $44.20M |
Cash & Equivalents | $59.63K | $29.71K | $111.77K | $57.74K |
Free Cash Flow OCF − CapEx | $-6.63M | $-5.64M | $-4.97M | $-6.01M |
Shares Outstanding | 4.20M | 4.22M | 4.22M | 4.23M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.